Loading…
GeoVax Labs, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in GOVX.
▼ -100.0% over 5Y.
today you would have $0.22▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $4.28 | $61.75 | $135.38 | $236.25 | |
| P/S | 6.6x | 3.0x | 6.6x | — | 203.5x |
| P/B | 1.9x | 1.9x | 5.2x | 1.9x | 0.6x |
| EPS | -$22.40 | -$120.46 | -$357.25 | -$311.25 | |
| Profit margin | -862.34% | -862.34% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| VIVSVivoSim Labs, INC. | $0.29 | — | 0.2x | — | -343.10% | $3.82M |
| SPRCSciSparc Ltd. | $6.58 | 0.1x | 0.6x | — | -178.39% | $3.82M |
| ISPCiSpecimen Inc. | $1.54 | — | 0.1x | — | -968.47% | $3.88M |
| RDGTRidgetech Inc. | $1.00 |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Company description provided by Yahoo Finance.
| -631.98% |
| — |
| -17198.35% |
| ROE | -472.80% | -561.15% | -495.04% | -450.55% | -52.71% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.0x |
| — |
| -3.55% |
| $3.63M |
| SXTP60 Degrees Pharmaceuticals Inc | $1.03 | — | — | — | -332.85% | $3.62M |
| RDHLRedHill Biopharma Ltd. | $0.66 | — | 0.8x | — | — | $4.02M |